MEDI-557 Adult Dosing - CD-1092

Exclusion Criteria

• -inability to complete a follow-up period of 360 days
• -any condition in the opinion of investigator that would interfere with evaluation of IP or interpretation of subject safety or study results
• -concurrent enrollment in another clinical study
• -employees of the site or other individuals involved with the conduct of the study or immediate family members of such individuals
• -receipt of immunoglobulin or blood products within 60 days prior to randomziation
• -receipt of any investigational drug therapy within 6 months prior to IP dosing
• -clinically abnormal ECG at screening
• -blood donation in excess of 400mL, wihtin 6 months prior to randomization
• -previous receipt fo biologics
• -history of immunodeficiency
• -history of allergic disease or reactions likely to be exacerbated by any component of the IP
• -previous medical history or evidence of interurrent illness that may compromise the safety of the subject
• -positive lab test for Hep A, B, C or HIV
• -pregnancy or nursing mother
• -history of alcohol or drug abuse within past 2 years
• -positive urine Class A drug screen
• -acute illness within 7 days prior to randomization
• -fever >/= 99.5F witin 7 days prior to randomization
• -any drug therapy within 7 days prior to randomization
• -systolic BP >150mmHG and/or diastolic BP>90mmHg
• -receipt of vaccine within 14 days prior to randomization
• -abnormal study labs (hem/wbc/platelet/BUN - see protocol for specific information)